Biotech Values

[DewDiligence]

REGN tidbit re the futility of Macugen:

On yesterday’s MS webcast, REGN CEO Len Schleifer revealed that the phase-2 AMD trial for VEGF-Trap will not have a Macugen arm because no one wants Macugen anymore.

Since Lucentis is not yet on the market, the phase-2 for VEGF-Trap will not have a control arm per se but will instead contain multiple arms of VEGF-Trap in various doses and dosing schedules.